Kyverna Therapeutics (KYTX) Other Non-Current Assets (2023 - 2026)
Kyverna Therapeutics posted quarterly Other Non-Current Assets of $5.0 million for Q1 2026, up 800.18% year-on-year from $557000.0 in Q1 2025, and up 2.26% on a QoQ basis from $4.9 million in Q4 2025.
Kyverna Therapeutics (KYTX) has 4 years of Other Non-Current Assets data on file, last reported at $5.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 800.18% year-over-year to $5.0 million; the trailing twelve-month figure through Mar 2026 stood at $5.0 million (up 800.18% YoY), and the FY2025 full-year result was $4.9 million, up 717.17% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $5.0 million, up from $4.9 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $5.0 million in Q1 2026 and bottomed at $551000.0 in Q3 2025.
- The 4-year median for Other Non-Current Assets is $600000.0 (2023), against an average of $1.9 million.
- The widest annual swing landed in 2025, when Other Non-Current Assets plunged 70.63%; it then soared 800.18% in 2026.
- A 4-year view of Other Non-Current Assets shows it stood at $600000.0 in 2023, then changed by 0.0% to $600000.0 in 2024, then surged by 717.17% to $4.9 million in 2025, then gained by 2.26% to $5.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $5.0 million (Q1 2026), $4.9 million (Q4 2025), and $551000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Kyverna Therapeutics | 497.98 Mn | 265.03 Mn | - | 5.01 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.01 Mn |
| Dec 31, 2025 | 4.90 Mn |
| Sep 30, 2025 | 551,000.00 |
| Jun 30, 2025 | 4.05 Mn |
| Mar 31, 2025 | 557,000.00 |
| Dec 31, 2024 | 600,000.00 |
| Sep 30, 2024 | 1.88 Mn |
| Jun 30, 2024 | 574,000.00 |
| Mar 31, 2024 | 570,000.00 |
| Dec 31, 2023 | 600,000.00 |